Abstract
Celanese has signed two agreements to promote the use of its ethylene vinyl acetate–based drug delivery technology, VitalDose. The chemical maker will work with Alessa Therapeutics to develop sustained–release oncology drugs using technology from both firms. Meanwhile, Celanese and Johns Hopkins University’s Department of Ophthamology will study sustained delivery of drugs for retinal disorders to the suprachoroidal space in the eye.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
